
How a Personalized Therapy Made From Your Own Tumor Could Help Keep Melanoma From Coming Back
Michael Postow, M.D., explains how intismeran autogene, a personalized vaccine made from a patient’s own tumor, helped lower melanoma recurrence in a Phase 3 trial.
By
Lana Pine| Published on November 18, 2026
Fact checked by:
Afton Woodward4 min read
A personalized cancer vaccine built from a patient’s own tumor may help keep melanoma from coming back after surgery. In the Phase 3 INTerpath-001 trial, adding intismeran autogene to the immunotherapy Keytruda (pembrolizumab) led to a 42% reduction in the risk of recurrence or death compared with Keytruda alone.
Merck and Moderna, which are developing the therapy together, presented the results at the European Society for Medical Oncology Congress 2026, and the findings were accepted for publication in the New England Journal of Medicine. The Educated Patient spoke with Michael Postow, M.D., chief of the Melanoma Service at Memorial Sloan Kettering Cancer Center, about what the results mean for patients.
A Vaccine Made From Your Own Tumor
Intismeran autogene is a personalized therapy that boosts the immune system to find and attack microscopic melanoma cells that may remain after surgery, Postow explained.
To make it, scientists perform genetic testing on a patient’s surgically removed melanoma to find abnormalities unique to the cancer, called neoantigens. The therapy is then designed to help the immune system recognize those targets. Each dose contains synthetic mRNA encoding up to 34 neoantigens.
Because it’s built from each person’s tumor, no two patients receive the same version.
“It is the ultimate personalized cancer treatment, made in a bespoke manner for each patient based on their own melanoma that has been surgically removed,” Postow said.
What the Trial Found
The trial included 1,137 patients with completely resected Stage IIB–IV cutaneous melanoma. Patients received Keytruda with either intismeran or a placebo for about a year.
At two years, 82.2% of patients on intismeran plus Keytruda were alive without recurrence, compared with 70.0% on Keytruda alone. The combination also led to a 38% reduction in the risk of distant metastasis or death, meaning melanoma spreading to distant parts of the body.
According to Postow, this means adding intismeran to the usual treatment reduced the number of patients whose melanoma ever came back after it was completely removed.
Rates of more severe side effects were similar between groups: Grade 3-5 treatment-related adverse events occurred in 14.2% of patients on the combination versus 13.4% on Keytruda alone. The most common side effects with the combination were fever (52.2%), injection site pain (51.0%) and fatigue (38.5%).
Why the Benefit Takes Time
In the first six months, the two groups performed similarly. After that, the combination showed a 58% reduction in recurrence or death.
Postow said the delay makes sense. Intismeran can take about six weeks to make, and like most vaccines, it takes time to strengthen the immune response.
He added that patients can take comfort in knowing Keytruda alone still lowers the risk of melanoma returning after surgery, so if intismeran becomes available, patients could start Keytruda first while their vaccine is made. “In the future, the time to make intismeran may shorten, which could also result in earlier benefit,” he said.
When Patients Might Have Access
Intismeran autogene isn’t approved by the U.S. Food and Drug Administration, and overall survival data are not yet mature. Merck and Moderna state they are engaging with regulatory authorities based on these data, and no submission or approval date was given.
Outside of clinical trials, the therapy isn’t available, Postow said. He encourages patients to ask their oncologist about intismeran and clinical trials, but noted that most patients who need melanoma treatment right now should move forward with standard immunotherapy, since trials are open only in very specific situations.
He expects the therapy may matter most for people diagnosed with melanoma in the future, or for current patients who develop a new melanoma that needs to be surgically removed.

